Response Prediction in Oncology Clinical Trials

Life Sciences, Clinical Trials, Pharmaceutical, Drug Discovery & Development,
  • Friday, October 21, 2022

The failure rate of late-stage oncology clinical trials is one of the highest across therapeutic areas, whereas many promising early-stage studies may be prematurely abandoned due to presumably false negative results.

With artificial intelligence (AI) and technology, the relationship between tumour changes and tumour assessment endpoints (ORR, PFS etc.) can be modelled to enhance understanding of the drug mechanism of action in clinical oncology studies.

Join this webinar to meet IAG’s expert team and discuss the latest technological innovations and advanced imaging to support success of oncology clinical trials through quantitative insights.


Prof. Sotirios Bisdas, IAG

Professor Sotirios Bisdas, MD, PhD, MSc, Image Analysis Group

Prof. Bisdas is the Head of Neuro-Oncology and Neurology clinical research at IAG, a neuroradiologist and Senior Lecturer at the Institute of Neurology, UCL, London, UK and Professor in Radiology at the University of Tübingen, Germany. Prof. Bisdas is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions.

Message Presenter
Dr. Anitha Singareddy, MD, Image Analysis Group

Dr. Anitha Singareddy, MD, Image Analysis Group

Dr. Singareddy is the Head of Medical Affairs at IAG, a board-certified physician with more than 13 years of experience in clinical research and CRO industry with extensive experience in oncology and haematology clinical trials (medical imaging).

Her expertise includes medical imaging, implementation of study protocols, and implementation of complex scientific assessment criteria in oncology, haematology, and other indications and their respective assessment criteria.

Message Presenter
Julia O’Lynn, Image Analysis Group

Julia O’Lynn, Director of Imaging, Image Analysis Group

Julia is Director of Imaging at IAG with extensive expertise in radiologic cross-sectional imaging, Julia has in-depth expertise in clinical trial design, advising life science companies how to use imaging-based markers to accelerate their drug development and ensure standardized imaging across multi-center trials.

Message Presenter

Who Should Attend?

Those who are involved in clinical trials from pharma, biotech and CRO backgrounds:

  • Protocol Development Team & Regulatory Submission Strategists
  • Pharmaceutical and Biotech executive teams
  • Chief Medical Officer
  • Chief Scientific Officer
  • Principal Investigators and Key Opinion Leaders
  • Radiologists
  • Medical Directors and Medical Leads
  • Clinical Researchers

What You Will Learn

Attendees will learn about:

  •  Using quantitative imaging methods to address the fundamental limitations of:
    • RECIST (Response Evaluation Criteria in Solid Tumours)
    • RANO (Response Assessment in Neuro-Oncology)
    • mRANO (Modified Radiographic Response Assessment in Neuro-Oncology)
  • Advanced quantitative insights into tumour characteristics
  • New techniques and their emergence in clinical trials
  • Deployment of multi-parametric approach for prediction of response
  • A cloud platform for robust imaging data management — DYNAMIKA


Xtalks Partner

IAG, Image Analysis Group

IAG, Image Analysis Group is a leading medical imaging expert company driving the use of quantitative imaging as an early evidence for drug development. We improve speed and reproducibility of radiological reviews with Computer-Aided workflows and bring smart often AI driven methodologies to extract the full spectrum of information from medical images. Thus, giving biotech or pharma companies early powerful efficacy data in clinical trials.

Learn more:

Reach out: [email protected]

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account